Compare Stocks: PGEN, KRYS, ABVX, and PTGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$112.39 -1.7%	$124.16	$69.81 ▼ $148.83	$9.81B	1.03	1.45 million shs	480,834 shs
KRYS Krystal Biotech	$350.12 -2.1%	$348.57	$136.73 ▼ $382.54	$10.36B	0.53	337,523 shs	65,103 shs
PGEN Precigen	$6.98 -2.9%	$6.01	$2.99 ▼ $7.72	$2.49B	1.02	4.69 million shs	1.56 million shs
PTGX Protagonist Therapeutics	$142.84 -4.5%	$137.88	$54.50 ▼ $160.81	$9.24B	1.78	714,717 shs	273,371 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-1.91%	-3.29%	-7.99%	-13.82%	+43.90%
KRYS Krystal Biotech	-0.64%	+6.06%	-1.86%	+15.67%	+142.12%
PGEN Precigen	-3.10%	-3.36%	+30.02%	+65.67%	+56.64%
PTGX Protagonist Therapeutics	-1.32%	-0.79%	+9.25%	+50.16%	+143.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$112.39 -1.7%	$124.16	$69.81 ▼ $148.83	$9.81B	1.03	1.45 million shs	480,834 shs
KRYS Krystal Biotech	$350.12 -2.1%	$348.57	$136.73 ▼ $382.54	$10.36B	0.53	337,523 shs	65,103 shs
PGEN Precigen	$6.98 -2.9%	$6.01	$2.99 ▼ $7.72	$2.49B	1.02	4.69 million shs	1.56 million shs
PTGX Protagonist Therapeutics	$142.84 -4.5%	$137.88	$54.50 ▼ $160.81	$9.24B	1.78	714,717 shs	273,371 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-1.91%	-3.29%	-7.99%	-13.82%	+43.90%
KRYS Krystal Biotech	-0.64%	+6.06%	-1.86%	+15.67%	+142.12%
PGEN Precigen	-3.10%	-3.36%	+30.02%	+65.67%	+56.64%
PTGX Protagonist Therapeutics	-1.32%	-0.79%	+9.25%	+50.16%	+143.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.80	Moderate Buy	$156.50	39.27% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	4.32% Upside
PGEN Precigen	2.80	Moderate Buy	$14.50	108.63% Upside
PTGX Protagonist Therapeutics	2.94	Moderate Buy	$140.53	-1.54% Downside

Current Analyst Ratings Breakdown

Latest PGEN, KRYS, ABVX, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/17/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$112.00 ➝ $178.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/11/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	PTGX Protagonist Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $170.00
8/10/2026	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$118.00 ➝ $173.00
8/10/2026	PTGX Protagonist Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy
8/10/2026	PTGX Protagonist Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$110.00 ➝ $186.00
8/7/2026	PTGX Protagonist Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$151.00 ➝ $153.00

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
KRYS Krystal Biotech	$389.13M	26.64	$7.10 per share	49.35	$45.92 per share	7.63
PGEN Precigen	$85.72M	28.91	N/A	N/A	$0.12 per share	57.92
PTGX Protagonist Therapeutics	$46.02M	200.70	N/A	N/A	$13.01 per share	10.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	43.89	37.54	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	8.08	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	138.57	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest PGEN, KRYS, ABVX, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9585	N/A	N/A	N/A	$0.78 million	N/A
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
KRYS Krystal Biotech	N/A	8.32	7.96
PGEN Precigen	2.15	4.58	3.89
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
KRYS Krystal Biotech	86.29%
PGEN Precigen	33.51%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
KRYS Krystal Biotech	13.10%
PGEN Precigen	41.40%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	87.25 million	N/A	Not Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
PGEN Precigen	190	356.51 million	208.92 million	Optionable
PTGX Protagonist Therapeutics	120	64.71 million	61.35 million	Optionable

PGEN, KRYS, ABVX, and PTGX Headlines

Recent News About These Companies

Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX

August 28 at 3:27 AM | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Protagonist Therapeutics, Inc. $PTGX

August 28 at 3:20 AM | marketbeat.com

Seven Fleet Capital Management LP Purchases 41,400 Shares of Protagonist Therapeutics, Inc. $PTGX

August 27 at 6:24 AM | marketbeat.com

9,414 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by J. Goldman & Co LP

August 27 at 5:28 AM | marketbeat.com

Artia Global Partners LP Takes $2.81 Million Position in Protagonist Therapeutics, Inc. $PTGX

August 27 at 3:13 AM | marketbeat.com

Jupiter Topco LLC Takes $261.04 Million Position in Protagonist Therapeutics, Inc. $PTGX

August 26 at 6:16 AM | marketbeat.com

Elmind Capital LP Invests $4.66 Billion in Protagonist Therapeutics, Inc. $PTGX

August 26 at 4:24 AM | marketbeat.com

EFG International AG Buys Shares of 40,501 Protagonist Therapeutics, Inc. $PTGX

August 26 at 4:24 AM | marketbeat.com

Castleark Management LLC Buys Shares of 50,570 Protagonist Therapeutics, Inc. $PTGX

August 26 at 4:16 AM | marketbeat.com

Protagonist Therapeutics, Inc. $PTGX Shares Bought by Algert Global LLC

August 26 at 3:04 AM | marketbeat.com

ADAR1 Capital Management LLC Makes New $117.78 Million Investment in Protagonist Therapeutics, Inc. $PTGX

August 26 at 3:03 AM | marketbeat.com

Protagonist Therapeutics, Inc. (PTGX)

August 25 at 7:11 AM | finance.yahoo.com

Northwestern Mutual Wealth Management Co. Purchases New Shares in Protagonist Therapeutics, Inc. $PTGX

August 24, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) and NeuroSense Therapeutics (NASDAQ:NRSN) Head-To-Head Survey

August 24, 2026 | americanbankingnews.com

Deutsche Bank AG Invests $17.39 Million in Protagonist Therapeutics, Inc. $PTGX

August 23, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded by Wall Street Zen to Strong-Buy Rating

August 22, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Protagonist Therapeutics, Inc. $PTGX

August 21, 2026 | marketbeat.com

248,322 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Eagle Health Investments LP

August 20, 2026 | marketbeat.com

Great Lakes Advisors LLC Invests $6.97 Million in Protagonist Therapeutics, Inc. $PTGX

August 20, 2026 | marketbeat.com

BMO Capital Markets Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

August 19, 2026 | americanbankingnews.com

Protagonist Therapeutics Reports Granting of Inducement Awards

August 18, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, KRYS, ABVX, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

$112.39 -1.91 (-1.67%)

As of 02:04 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Krystal Biotech NASDAQ:KRYS

$350.12 -7.34 (-2.05%)

As of 02:01 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Precigen NASDAQ:PGEN

$6.98 -0.21 (-2.92%)

As of 02:04 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Protagonist Therapeutics NASDAQ:PTGX

$142.84 -6.66 (-4.45%)

As of 02:00 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PGEN, KRYS, ABVX, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PGEN, KRYS, ABVX, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PGEN, KRYS, ABVX, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, KRYS, ABVX, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

Krystal Biotech NASDAQ:KRYS

Precigen NASDAQ:PGEN

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PGEN, KRYS, ABVX, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PGEN, KRYS, ABVX, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PGEN, KRYS, ABVX, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, KRYS, ABVX, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

Krystal Biotech NASDAQ:KRYS

Precigen NASDAQ:PGEN

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools